CVS disorder Flashcards
CVS disorder
Hypertension
Ischemic Heart Disease
Cognitive Heart Failure
Hypertension
Any sustained BP systolic/diastolic above 140/90
At least 3 measurement
Asymptomatic
Hypertension Stage
Prehypertensive 120/80 40-60 years
Stage 1 140/90
Stage 2 160/100
Hypertension Complication
Heart attack Coronary heart disease Stroke Renal failure Blindness
Mean Arterial Pressure(MAP)= CO x Total Peripheral Resistance(TPR)
CO= Heart rate, Stroke volume(Contractility, Filling pressure(Venous tone, Blood volume)) TPR= Blood volume Arteriolar diameter
Major mechanism control BP
Neural = Ans(PSNS,SymNS)
Hormonal
Local Factor = Alter blood vessel
Catecholamine
Adrenal Hormonal control BP mechanism
Phaeochromacytoma(tumor)
Increase sec
Aldosterone
Adrenal Hormonal control BP mechanism
Na, H20 retention
Inc BP
Angiotensin II
Renal renin(SymNS) Hormonal control
Stimulate sympa NS
Affect aldosterone release
Inc BV, hypertension
Antihypertension Drug Target
CNS, ANS - Decrease sympatetic tone Heart- Decrease cardiac output Veins - Dilate - Decrease preload Arterioles - Dilate- Decrease afterload Kidney- Increase diuresis- Inhibit RAA system
Type of hypertension
White Coat
Essential
Secondary
White Coat
Stress associated with office/environment
Need 3-6 independent measurement
Essential
No known cause(95%)
Pharmacological theraphy
Secondary
Increase BP secondary to pathology
Renal Artery Stenosis
Secondary Hypertension
Isocheimal result increase AR(Angiotensinogen Renin)
Phaeochromocytoma
Secondary Hypertension
Tumor in chromafin cell of adrenal gland
Hypersecretion of adrenal catecholamine
Aortic Coarctation
Secondary Hypertension Severe congestion at arch & increase upper body pressure to maintain lower body perfusion Back BV are very dilated
Adrenal Tumor
Secondary Hypertension
Hypersecretion of glycocorticoid(aldosterone)
Hyperthyroidism
Secondary Hypertension
Increase CO with palpitation
General Hypertension treatment strategy
Diagnosis- At least 3 independent measurement
Determination of primary vs secondary hypertension
If secondary treat underlying pathology
If primary initiate lifestyle change
next Pharmacological treatment essential hypertension
lifestyle change include
Weight reduction Salt reduction Withdrawal of drug Tobacco Alcohol Stress reduction
Class of Anti-Hypertensive Drug
Diuretic(de BV) Peripheral a1 adrenergic antagonist Central Sympatholytic a2 agonist B-adrenergic antagonist Anti-angiotensin II Ca++ channel blocker Vasodilator
Type of Diuretics
Thiazides
Loop Diuretic
K+ Sparing
Osmotic(HTN emergency)
Hydrochlorothiazide
Thiazides Mild to moderate HTN Direct vasodilator action Start with low potency diuretic Used with low na, high k
Furosemide
Loop Diuretic
Severe HTN, with CHF
Spironolactone
K+ Sparing
Combination with other drug
Week, prevent K loss
Diuretic Site of Action
Renal nephron
Different segment of nephron
Diuretic MOA
Inc urinary Na & H2O excretion,
dec extracellular fluid, plasma vol
All decrease Na reabsorption
Act on renal system, transporter, hormones, ion channel
Diuretic Effect on cardiovascular
Acute decrease in CO
Chronic decrease TPR, CO return normal
Compensate Na+ retaining reflex
Diuretic ADR
Hypokalemia Hyperglycemia(Thiazides) Hyperuricemia(gout) Dizziness Electrolyte imbalance Hyperlipidemia
Diuretic Contraindication
Hypersensitivity Compromised kidney function Cardiac glycosides Hypovolemia Hyponatremia
MOA antagonist a1
Competitive antagonist a1 receptor on sm
Site of action a1 antagonist
Peripheral arterioles, sm
Block a1= vasodilator
Major mech sym con of BP
Adr a1 antagonist
Postural Hypotension
Tachycardia
Nausea, drowsiness
Postural Hypotension
Adr a1 antagonist
1st dose syncope
Take smaller dose
Take when sitting
Type a1 antagonist
Prazosin(Miniores)
Terazosin(Hytrin)
a1 antagonist Fx to CVS
Vasodilation, reduce peripheral resistance
a1 antagonist Contraindication
Hypersensitivity
a1 antagonist Uses
Diabetes, asthma, hypercholesterolemia
Mild to moderate HTN
Often used with diuretic, B-antagonist
Clonidine
Central Sympatholytic a2 agonist
Direct agonist
Rebound increase in BP
Prolong used Salt, water retension Add diuretic
Methyldopa
Central Sympatholytic a2 agonist Converted to methylnorepinephrin False neurotrans DOC in pregnancy Prolong used Salt, water retension Add diuretic
Site of action a2 agonist
CNS Medullary Cardiovascular Center
MOA a2 agonist
activate CENTRAL a2 receptor
Peripheral sym inhibition
Decrease norepinephrine release
Decreased vasoconstriction Decrease TPR